CN1517124A - Chinese medicinal composition possessing antipyretic and its preparation method and quality control method - Google Patents
Chinese medicinal composition possessing antipyretic and its preparation method and quality control method Download PDFInfo
- Publication number
- CN1517124A CN1517124A CNA200410000134XA CN200410000134A CN1517124A CN 1517124 A CN1517124 A CN 1517124A CN A200410000134X A CNA200410000134X A CN A200410000134XA CN 200410000134 A CN200410000134 A CN 200410000134A CN 1517124 A CN1517124 A CN 1517124A
- Authority
- CN
- China
- Prior art keywords
- solution
- preparation
- adds
- methanol
- need testing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003908 quality control method Methods 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 126
- 239000000203 mixture Substances 0.000 title claims description 22
- 230000001754 anti-pyretic effect Effects 0.000 title abstract description 5
- 239000002221 antipyretic Substances 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 58
- 239000000843 powder Substances 0.000 claims abstract description 49
- 239000002904 solvent Substances 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 8
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 207
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 171
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 167
- 238000012360 testing method Methods 0.000 claims description 117
- 238000002347 injection Methods 0.000 claims description 71
- 239000007924 injection Substances 0.000 claims description 71
- 239000013558 reference substance Substances 0.000 claims description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- 241000628997 Flos Species 0.000 claims description 47
- 239000006071 cream Substances 0.000 claims description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 40
- 239000007788 liquid Substances 0.000 claims description 40
- 239000000706 filtrate Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 34
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 33
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 33
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 33
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 33
- 229940074393 chlorogenic acid Drugs 0.000 claims description 33
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 33
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 33
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 33
- 239000007864 aqueous solution Substances 0.000 claims description 27
- 239000002131 composite material Substances 0.000 claims description 23
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 claims description 22
- 238000010438 heat treatment Methods 0.000 claims description 22
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 238000007689 inspection Methods 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 238000000605 extraction Methods 0.000 claims description 19
- 239000012567 medical material Substances 0.000 claims description 19
- 239000000341 volatile oil Substances 0.000 claims description 19
- 238000004809 thin layer chromatography Methods 0.000 claims description 18
- 239000000543 intermediate Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000004321 preservation Methods 0.000 claims description 16
- 238000011003 system suitability test Methods 0.000 claims description 15
- 238000001291 vacuum drying Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 12
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000000202 analgesic effect Effects 0.000 claims description 9
- 239000000890 drug combination Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical compound OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 7
- 239000012895 dilution Substances 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 7
- -1 filter Substances 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- GSEMDSHDLFBDML-UHFFFAOYSA-N O.OC=O.CCOC(C)=O Chemical compound O.OC=O.CCOC(C)=O GSEMDSHDLFBDML-UHFFFAOYSA-N 0.000 claims description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 6
- 235000019800 disodium phosphate Nutrition 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 241000256844 Apis mellifera Species 0.000 claims description 5
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 5
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 241001625593 Aspergillus fructus Species 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- FOHSWKNHIIJOPU-UHFFFAOYSA-L [Na+].[Na+].CC#N.OP([O-])([O-])=O Chemical compound [Na+].[Na+].CC#N.OP([O-])([O-])=O FOHSWKNHIIJOPU-UHFFFAOYSA-L 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000012159 carrier gas Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 238000012850 discrimination method Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000004817 gas chromatography Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000010453 quartz Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000010265 sodium sulphite Nutrition 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 6
- 241001570521 Lonicera periclymenum Species 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 3
- 241000157835 Gardenia Species 0.000 claims 2
- 241000245240 Lonicera Species 0.000 claims 2
- 206010004054 Bacterial upper respiratory tract infections Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003643 water by type Substances 0.000 claims 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract description 4
- 235000001405 Artemisia annua Nutrition 0.000 abstract 1
- 240000000011 Artemisia annua Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 description 33
- 230000001988 toxicity Effects 0.000 description 33
- 230000001047 pyretic effect Effects 0.000 description 31
- 238000005057 refrigeration Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 206010020741 Hyperpyrexia Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229940100050 virazole Drugs 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000008923 Qingkailing Substances 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940120889 dipyrone Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- JJBCTCGUOQYZHK-ZSCHJXSPSA-N 2-acetyloxybenzoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O JJBCTCGUOQYZHK-ZSCHJXSPSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010033971 Paratyphoid fever Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- KAQQQJHJILHTCD-UHFFFAOYSA-N acetonitrile;chloroform;methanol Chemical compound OC.CC#N.ClC(Cl)Cl KAQQQJHJILHTCD-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960004105 carbasalate calcium Drugs 0.000 description 1
- VYMUGTALCSPLDM-UHFFFAOYSA-L carbasalate calcium Chemical compound [Ca+2].NC(N)=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O VYMUGTALCSPLDM-UHFFFAOYSA-L 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940085771 feverall Drugs 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine with antipyretic, antiviral and antibacterial functions is prepared from sweet wormwood, honeysuckle flower and capejasmine fruit through preparing their dried extract powder and proportionally mixing with excipient and solubilizer. Its quality control method is also disclosed.
Description
Invention field
The present invention relates to a kind of Chinese medicine composition, particularly have the Chinese medicine composition of refrigeration function, relate to the preparation method and the method for quality control of said composition simultaneously.
Background technology
External wind heat syndrome is that function weakens outside human body is defended, and can not regulate in the strain, and pathogenic factor is from mouth and nose, fur invasion, and the evil lung of violating is defended, and defends table and gets along well and cause a disease.Be common in diseases such as upper respiratory tract infection, influenza, acute bronchitis, pneumonia, cardinal symptom has hyperpyrexia, micro evil wind, nasal obstruction, watery nasal discharge, a general pain, cough, thirsty, laryngopharynx swelling and pain, tongue tip side of red, floating and rapid pulse etc.According to statistics, because heating causes death, the whole world has at least more than 2,000,000 every year, and especially the hyperpyrexia that causes of upper respiratory tract infection and influenza is having a strong impact on the healthy of people, and the expense that is used for the treatment of every year is up to tens yuan; Therefore, controlling affection due to external wind and heat effectively, is the arduous and urgent task of medical worker.
The reason that causes hyperpyrexia has many, as viral infection, bacterial infection, mycoplasma infection, parasitic infection etc., and the hyperpyrexia that causes of virus or bacterial infection commonly wherein.Heating was a kind of defense reaction of body originally.It can accelerate metabolic processes, and antiviral growth and breeding impels leukocytosis, strengthens the function (cytophagous activity, antibody generation and liver detoxification ability etc.) of reticuloendothelial system, helps the recovery of disease.Pattern of fever all has important value to diagnosis, judgement therapeutic effect and the prognosis of disease.Heating also can make physical demands on the other hand, causes headache, insomnia even convulsions.Excessive heat (more than 41 ℃) or lasting heating also can cause permanent brain damage and cause death dying.Therefore, it is necessary heating more than the moderate suitably being used antipyretic.
Doctor trained in Western medicine mainly is to use antipyretic analgesic (as non-steroidal drugs such as carbasalate calcium, aspirin lysine, ibuprofen, acetaminophen, naproxens) and antiviral antibacterials (if any acyclovir, Buddha's warrior attendant gastral cavity amine, virazole, penicillin etc. to the treatment of heating.) though it brings down a fever soon, toxic and side effects is big, mainly shows as nauseatingly, and gastrointestinal reaction such as vomiting, diarrhoea, stomachache and to hematoblastic influence, is had a liking for symptoms such as saliva, insomnia, erythra at also accidental dizziness.And the traditional Chinese medical science has good effect, characteristics that toxic and side effects is little on this disease of treatment, and therefore, developing the antibiotic analgesic new Chinese medicine of new highly efficient anti-virus has wide prospect.
Summary of the invention
One object of the present invention is to disclose a kind of new Chinese medicine composition with refrigeration function; Another object of the present invention is a kind of new method with refrigeration function Chinese medicine composition of open preparation; The object of the invention also is to disclose a kind of method of quality control of new Chinese medicine composition.
The crude drug of pharmaceutical composition of the present invention is formed and proportioning following (by weight):
Herba Artemisiae Annuae 1000-1400 weight portion Flos Lonicerae 600-900 weight portion Fructus Gardeniae 500-700 weight portion
This preparation of drug combination method: above three flavors, Flos Lonicerae, Herba Artemisiae Annuae add 13-18 times of water gaging and soaked 2-4 hour, and heating decocts distillation 1-3 time, and each 1-3 hour, collect volatile oil simultaneously, standby.Merge decoction liquor, being evaporated to relative density is 1.03~1.08, and high speed centrifugation is got supernatant, the classification ultrafiltration, and it is 1.08~1.15 that ultrafiltrate is evaporated to 40-60 ℃ of relative density, vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder.Fructus Gardeniae is ground into coarse powder, doubly measures the 60-85% alcohol heating reflux 1-3 time with 5-7, each 1-2 hour, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1-2: 1-2, transfer pH4.0 with hydrochloric acid, 100 ℃ were heated 0.5-1.5 hour, cold preservation 10-14 hour, filter, it is 1.10~1.12 that filtrate is concentrated into 45-55 ℃ of relative density, vacuum drying gets the Fructus Gardeniae dried cream powder.Get Herba Artemisiae Annuae, Flos Lonicerae volatile oil through adjuvant behind the routine parcel, with above-mentioned dried cream powder mixing.At last directly or add pharmaceutically acceptable excipient and make clinical acceptable forms, as tablet, oral liquid, capsule, granule, ejection preparation through conventional operation.It is as solvent, disintegrating agent, correctives, antiseptic, coloring agent etc. that medicine of the present invention can add conventional drug excipient.
The preparation method of ejection preparation of the present invention: get Herba Artemisiae Annuae, Flos Lonicerae volatile oil, after adding 5-7 weight portion poloxamer 108 grinding mixings, add in 900 parts by volume (weight portion/parts by volume the is g/ml herein) water for injection, stirring makes clear and bright, add Flos Lonicerae in the above-mentioned technology, Herba Artemisiae Annuae dried cream powder again, the Fructus Gardeniae dried cream powder stirs and makes dissolving, and transferring pH value with sodium hydroxide solution is 7.5~8.0, adds injection water to 1000 parts by volume.Use G
4Sintered filter funnel filters, embedding, and 100 ℃ of flowing steam sterilizations promptly get injection, every 10ml; Can also make lyophilized injectable powder by freeze-drying in embedding, sterilization back; Or in water for injection, add Flos Lonicerae, Herba Artemisiae Annuae dried cream powder, during the Fructus Gardeniae dried cream powder, add 0.2~5 times caffolding agent of total dried cream powder again, as glucose or mannitol or sodium chloride etc., dissolving, transferring pH value is 7.5~8.0, filters, sterilizes, packing, injectable powder is made in lyophilization.Or, make other injection types such as suspension type injection, infusion solution etc. by common process.
Pharmaceutical composition of the present invention can also adopt following method preparation:
Herba Artemisiae Annuae 1000-1400 weight portion Flos Lonicerae 600-900 weight portion Fructus Gardeniae 500-700 weight portion
The preparation of Flos Lonicerae, Herba Artemisiae Annuae dried cream powder: Flos Lonicerae extracting in water 1-3 time (80-100 ℃), each 1-2 hour, amount of water was 9-16 times, extracting solution is put in addition; After Herba Artemisiae Annuae adds 3-6 times of water gaging and runs through, extracted volatile oil in vapor distillation 5-8 hour, volatile oil is put in addition, extract Flos Lonicerae and Herba Artemisiae Annuae extracting solution, filter, being evaporated to relative density is 1.10 (60 ℃), adds ethanol and makes and contain the alcohol amount and be 70-80%, left standstill 20-36 hour, filter, it is 1.20 (60 ℃) that filtrate decompression is concentrated into relative density, and transferring pH value with hydrochloric acid is about 1.8-2.3, with equivalent ethyl acetate extraction 9-12 time, get extract, be evaporated to no ethyl acetate flavor, inclining concentrated solution, vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder;
The preparation of Fructus Gardeniae dried cream powder: Fructus Gardeniae is ground into coarse powder, doubly measures the 70-90% alcohol heating reflux 1-3 time with 5-8, each 1-2 hour, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1: 1, transferring Ph with hydrochloric acid is 2.5-3.5, and 100 ℃ were heated 1-2 hour, added the hard paraffin of 1% medical material amount, stir evenly, cold preservation 10-14 hour, filter, the n-butanol extraction of filtrate usefulness equivalent 5-7 time, concentrating under reduced pressure is to no n-butyl alcohol flavor, and vacuum drying gets the Fructus Gardeniae dried cream powder.
Above-mentioned Flos Lonicerae, Herba Artemisiae Annuae dried cream powder, two kinds of intermediate of Fructus Gardeniae dried cream powder, can be directly or add pharmaceutically acceptable excipient or clinical acceptable forms is made in solubilizing agent through conventional operation, as capsule, tablet, oral liquid, granule, injection etc.
Described injection can further make with following method: get water for injection 800-1200 parts by volume and boil, drop into above-mentioned two intermediate that make, stir evenly, seethe with excitement after 3-7 minute, be cooled to room temperature, cold preservation 20-36 hour, filter, it is 2-3 that filtrate is transferred PH, adds 1% active carbon, boiled cold preservation 20-36 hour after-filtration, filtrate 8-14 minute, be heated to boiling, transferring PH in the heating process is 5.05, the 9-13 minute cool to room temperature that seethe with excitement, cold preservation 40-58 hour, filter, add 0.3-0.8 weight portion sodium sulfite, standardize solution 1000 parts by volume stir and get solution 50 parts by volume, be heated to 65 ℃ and add tween 80 3-5 parts by volume, stir evenly, add volatile oil, stir evenly, (molecular weight is 30,000 to filter ultrafiltration, 10,000), cross the microporous filter membrane of 0.22 μ m, packing, flowing steam sterilization 35-50min.
Described parts by volume/weight portion is corresponding with g/ml.
The method of quality control that this compositions is made medicament comprises discriminating and/or assay and/or inspection.
Discrimination method comprises a kind of and/or several in the following method: a. gets this compositions ejection preparation 5ml, adds 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 1-3 time, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Extracting honeysuckle control medicinal material 0.5g adds water 20ml backflow 0.5-1.5 hour in addition, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the chlorogenic acid reference substance again, add methanol and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography (" appendix VIB of Chinese pharmacopoeia nineteen ninety-five version) test, draw each 4 μ l of above-mentioned three kinds of solution, put respectively on same silica gel H plate, with 8-9: 0.5-1.5: 0.5 ethyl acetate-formic acid-water is developing solvent, launches, and takes out, dry, inspection is known under ultra-violet lamp; In the test sample chromatograph, respectively with Flos Lonicerae control medicinal material and the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color; B. get this compositions ejection preparation 5ml, add water saturated n-butyl alcohol collection and drive 1-3 time, each 10ml merges n-butyl alcohol liquid, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Fructus Gardeniae control medicinal material 1g, adds water 15-25ml and refluxes 1 hour, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the gardenoside reference substance again, add methanol and make the solution that every 1ml contains 4mg, in contrast product solution; According to thin layer chromatography (" appendix vIB of Chinese pharmacopoeia nineteen ninety-five version) test, draw above-mentioned three kinds of solution each 51, put respectively on same high-efficient silica gel GF254 lamellae, with 6-8: 2-4: 1-3: 0.1-0.3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launch, take out, dry, inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle; With the corresponding position of Fructus Gardeniae control medicinal material chromatograph on, show the speckle of same color; C. get this compositions ejection preparation 5ml, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast; Test according to thin layer chromatography (appendix VIB of (Chinese Pharmacopoeia) nineteen ninety-five version), draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel G thin plate, with 7-9: 1-3: 1-3: 0.1-3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launch, take out, dry, inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
Assay comprises a kind of and/or several in the following method: a. Fructus Gardeniae salidroside content is measured, and measures according to high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia nineteen ninety-five version); Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica, and the 0.05mol/L sodium hydrogen phosphate is transferred pH6.0 with phosphoric acid, 80-90: 10-14 sodium hydrogen phosphate-acetonitrile is a mobile phase; Detect wavelength 237nm, theoretical tower; The plate number calculates by the gardenoside peak should be not less than 2500; The preparation of reference substance solution, precision take by weighing gardenoside reference substance 6mg, put in the 100ml measuring bottle, add the dissolving of 40-60% methanol aqueous solution and are diluted to scale, shake up, promptly; This compositions ejection preparation 1ml is measured in the preparation of need testing solution, precision, puts in the 100ml measuring bottle, adds the 40-60% methanol aqueous solution and is diluted to scale, shake up, precision is got 5ml again, puts in the 10ml measuring bottle, add the 40-60% methanol aqueous solution to scale, shake up, as need testing solution; Algoscopy, precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly; B. determination of chlorogenic acid, measure according to high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia nineteen ninety-five version), chromatographic condition and system suitability test, with octadecylsilane chemically bonded silica is filler, 1% 75-85: 15-25 aqueous acetic acid-methanol is mobile phase, the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid honeybee should be not less than 3000; The preparation of reference substance solution, precision take by weighing chlorogenic acid reference substance 6mg, put in the 100ml measuring bottle, add 1%0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; This compositions ejection preparation 1mL is measured in the preparation of need testing solution, precision, puts in the 100ml measuring bottle, adds 1%0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; Algoscopy, precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.
Inspection comprises following method:
The n-butyl alcohol determination of residual amount: by " Chinese pharmacopoeia appendix gas chromatography of version in 2000 and alcohol determining method are measured; Chromatographic condition and system suitability test, chromatographic column: SUPELCO company: SLMPLICLTY-WAX capillary quartz column (30m * 530 μ m * 1.0 μ m) chromatographic condition: carrier gas: N
2, shunt mode sample introduction not, injector temperature: 200 ℃, constant voltage mode: the average linear speed of pressure 10Kpa is 14cm/sec; Column temperature: 80 ℃ kept 1.5 minutes, rose to 120 ℃ with 5 ℃/min again, rose to 200 ℃ with 20 ℃/min again, kept 10 minutes; Number of theoretical plate calculates by the ethanol peak should be not less than 1500;
Reference substance solution preparation: precision is measured n-butyl alcohol 0.1ml and is put in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, and precision is measured 0.1ml, puts in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, as n-butyl alcohol contrast liquid;
Standard curve is drawn, accurate n-butyl alcohol contrast liquid 1 μ l, 2 μ l, 3 μ l, 4 μ l, the inject gas chromatograph drawn, record chromatographic peak trap integrated value is an abscissa with reference substance concentration, is vertical coordinate with the trap score value, the drawing standard curve gets the n-butyl alcohol standard curve;
The need testing solution preparation: get 1 bottle of this combination injection, inclining injection, puts in the conical flask, shakes up, as need testing solution;
Algoscopy: the accurate need testing solution 1 μ l that draws, inject gas chromatograph, record test sample chromatographic peak trap integrated value, the substitution standard curve calculates content; This combination injection contains n-butyl alcohol must not cross 10/1000000ths.
The present composition is being controlled antiviral, good effect is being arranged on antibiotic, analgesic, and said composition toxicity is very little, and clinical practice is safe and reliable.
Present composition preparation (pyretic toxicity injection for curing) refrigeration function that tool is stronger, and can be by rising and the interior life of giving birth to pyrogen IL-1 of inhibition that suppresses cAMP in heating animal brain spinal fluid, the blood; Various respiratory road Strain is caused the cultured cell pathological changes obvious inhibitory action is all arranged; Growth to the various bacteria bacterial strain also has certain inhibitory action; In addition tool antiinflammatory, enhancing body's immunological function preferably improves premunition.High, middle dosage also can be had an analgesic effect.
Present composition preparation production technique advanced person, method of quality control can carry out effective and stable control to the quality of product.
Following experimental example is used to further specify the present invention.
The refrigeration function of experimental example 1 pyretic toxicity injection for curing
Experiment material: 1, analgin injection, 2ml/ props up, 0.25g/ml, Jiangxi Pharmaceutical Factory, lot number 980,503 2,2,4-f dinitrophenol,DNP, Beijing Chemical Plant, lot number 980,726 3, typhoid fever, paratyphoid fever first and second triple vaccinies, Lanzhou biological factory, 990327
Experimental technique: the refrigeration function that triple vaccine is caused fever in rabbits, adopt the healthy male rabbit of the about 2kg of body weight, survey normal anus temperature 3 times preceding 2 day every day in experiment, choosing body temperature is no more than 0.2 ℃ 50 of animals in the fluctuation of 38.5-39.3 ℃ and every day and uses for experiment, be divided into 5 groups at random, experimentize under 20 ℃ of environment of room temperature.Auricular vein injection triple vaccine 0.8ml/kg body weight causes the hyperpyrexia pathological model, surveys body temperature behind the 1h, with the person that raises more than 0.5 ℃ as laboratory animal.3 test group are used pyretic toxicity injection for curing 5.08g/kg, 2.4g/kg and 1.27g/kg respectively, positive controls is given analgin injection 0.20g/kS, and blank group is given normal saline, all intravenous administration, injection speed is<0.2ml/min that injection back 1-5h surveys the anus temperature.Other gets 40 of qualified rabbit, experimental technique and animal grouping are the same, 3 test group are irritated stomach with the dosage of 5.08g/kg, 2.54g/kg and 1.27g/kg respectively with pyretic toxicity injection for curing dry powder respectively, and positive controls irritates stomach for analgin tablet 0.20g/kg, and blank group is given isopyknic normal saline.
Experimental result: L causes the refrigeration function of fever in rabbits to triple vaccine
Three dosage of pyretic toxicity injection for curing 1h after the iv administration begins that fever in rabbits due to the triple vaccine is had tangible refrigeration function, and with normal saline group ratio, animal heat decline statistical analysis has significant difference, and more rapid-action than gastric infusion, action effect is obvious.Analgin injection 0.20g/kg also has tangible antipyretic effect, shown in the table 1,2.
Table 1 pyretic toxicity injection for curing iV causes refrigeration function (n=10, the x ± s) of fever in rabbits to triple vaccine
Different time body temperature ℃ after the administration after the vaccinate before the group dosed administration
G/kg body temperature/℃ body temperature ℃ 1h 2h 3h 4h 5h
NS 1.0ml/kg 39.2±0.3 40.3±0.4 40.5±0.3 40.7±0.4 40.8±0.4 40.4±0.3 40.8±0.3
Pyretic toxicity is peaceful
1.27 38.9±0.4 40.2±0.3 39.2±0.4* 39.4±0.4 39.4±0.4* 39.6±0.5 39.7±0.4
Injection
2.54 38.8±0.3 40.1±0.4 38.4±0.3* 39.4±0.2* 39.4±0.2* 39.2±0.3* 39.4±0.3*
5.08 38.9±0.2 40.2±0.3 38.3±0.3* 39.4±0.2* 39.0±0.3* 39.4±0.4* 39.3±0.2*
Dipyrone
0.20 39.1±0.2 40.3±0.2 38.8±0.2* 39.0±0.3* 38.9±0.3* 39.2±0.2* 39.6±0.4
Injection
Compare * p<0.05 with the normal saline group
Table 2 pyretic toxicity injection for curing ig causes refrigeration function (n=10, the x ± s) of fever in rabbits to triple vaccine
Different time body temperature ℃ after the administration after the vaccinate before the dosed administration
Group
G/kg body temperature/℃ body temperature ℃ 1h 2h 3h 4h 5h
Matched group equivalent 39.2 ± 0.3 40.1 ± 0.8 40.4 ± 0.5 41.7 ± 0.8 40.9 ± 0.5 40.5 ± 0.5 40.9 ± 0.8
Pyretic toxicity is peaceful
1.27 39.2±0.4 40.2±0.8 40.2±0.5 40.1±0.8 40.1±0.4* 39.8±0.5* 39.8±0.4
Injection
2.54 39.3±0.3 40.8±0.4 40.2±0.6 39.8±0.5* 39.7±0.7 39.6±0.6* 39.5±0.6*
5.08 39.2±0.3 40.7±0.1 39.8±0.8 39.4±0.7* 39.5±0.6* 39.8±0.5 39.8±0.4*
Dipyrone
0.20 39.2±0.1 40.1±0.8 40.1±0.7 39.7±0.6 39.4±0.4* 39.6±0.2* 39.5±0.2*
Sheet
Compare * p<0.05 with the normal saline group
Conclusion: the peaceful large, medium and small dosage of vein heat injection poison all has refrigeration function in various degree, and peaceful oral more rapid-action than pyretic toxicity, effect is strong.The QINGKAILING group also has the better antipyretic effect.Rather big or middle dosage group of intravenous injection pyretic toxicity and QINGKAILING group there was no significant difference.The peaceful analgesic system of pyretic toxicity may with reduce brain ji spinal fluid in suck blood in cAMP content and the blood content of IL-1 relevant.
Experimental example 2 pyretic toxicity injection for curing preventing respiratory viruses effects
The effect of pyretic toxicity injection for curing treatment mice influenza toxicity pneumonia, with 60 of NIH mices, body weight 14-16 gram, divide 6 groups at random: virus control, normal control, positive control is pressed the high, medium and low dosage group of pyretic toxicity injection for curing.In infecting the first two day beginning intravenous administration, the 3rd day animal under the slight anesthesia of ether, every mice intranasal vaccination FMll5xLD50 virus liquid, the pyretic toxicity injection for curing of intravenous injection every day variable concentrations, once a day, continuous five days; The blank group gives the equal-volume normal saline, and the positive controls virazole is administered once every day, each 0.07g/kg.Cutd open mice extremely on the 6th, getting lung after weighing weighs, calculate lung exponential quantity (the lung weight in every 100g body weight) and lung index suppression ratio ([the average lung index of the average lung index-experimental group of virus control group] the average lung index of ÷ virus control group * 100%) one by one, compare with matched group, organize a t check.See Table 3
Table 3 pyretic toxicity injection for curing is to the effect (n=10) of mice influenza virus property pneumonia
Group dosage (g/kg) lung index (suppression ratio (%) the P value of x ± SD)
Virus control-1.74 ± 0.46--
Normal control-1.07 ± 0.29--
Virazole 0.02 1.13 ± 0.23 35.06<0.05
Pyretic toxicity injection for curing 20.30 1.06 ± 0.34 39.08<0.01
10.15 1.19±0.50 31.61 <0.01
5.08 1.62±0.56 6.90 >0.05
Annotate: P value system compares with the virus control group
The antibacterial action of experimental example 3 pyretic toxicity injection for curing
The preparation of Carnis Bovis seu Bubali cream soup body culture medium: take by weighing Carnis Bovis seu Bubali cream 0.3g, peptone 1.0g, sodium chloride 0.5g.Put into beaker, add a small amount of distilled water heat fused after, adding distil water is to 100ml again, 20g/dl hydrochlorinate sodium solution is regulated its pH value to 7.2-7.6 then, uses filter paper filtering.Package 103.4kPa (15 pounds) sterilization 20 minutes with conical flask.The preparation of pharmaceutical liquid culture medium: because experimental strain is more, be the formality that simplifies the operation, test with being sub-packed in small test tube behind the Boiling tube dilute liquid medicine more earlier.Get 10 Boiling tube number consecutivelies, put in vitro every pipe 10ml with pipette, extract Carnis Bovis seu Bubali cream soup body culture medium by the sterile working.Reuse pipette, extract pyretic toxicity injection for curing (2.6g/ml) 10ml puts into the 1st pipe, shake up repeatedly: then draw 10ml and put into the 2nd pipe from the 1st pipe, shake up repeatedly, the same 10mi that draws puts into the 3rd pipe ... medicinal liquid is diluted as 1: 2 successively, 1: 4,1: 8 ... 1: 1024, drug level was followed successively by 1.3000,0.6500,0.3250 ... 0.0010g/ml.Get aseptic small test tube numbering again, every kind of bacterial strain is with 11 test tubes, manages for 1~No. 10 and to put into successively by serial dilution medicinal liquid 1ml, and No. 11 test tubes are put into the Carnis Bovis seu Bubali cream soup body culture medium 1ml that does not contain medicine and managed in contrast.
The inoculation of bacterial strain and cultivation: each experimental strain is inoculated in the Carnis Bovis seu Bubali cream soup body culture medium in 37 ℃ of incubators, cultivated 16~18 hours, be diluted to 10-3 concentration with Carnis Bovis seu Bubali cream soup body culture medium or normal saline.Every kind of bacterial strain suspension inoculates 11 test tubes (containing 1 of 10 of variable concentrations medication tube and control tube), every pipe 0.1ml.In 37 ℃ of incubators, cultivated 24 hours, take out the bacterial growth situation of observing.As the drug liquid tube clarification, represent no bacterial growth, then this pipe medicine has antibacterial action; As be muddy, the expression antibacterial grows, and this pipe Chinese medicine does not have antibiotic effect.With the lowest concentration of drug of integral asepsis growth as the MIC of medicine to this bacterial strain.Experimental result shows that the pyretic toxicity injection for curing all has stronger bacteriostasis to various bacteria, to its minimal inhibitory concentration difference of different bacterium, sees Table 4
The antibacterial action (test tube method) of table 4 pyretic toxicity injection for curing
Bacterial strain minimum inhibitory concentration (MIC, g/ml) drug dilution degree
Bacillus typhi 0.0813 1: 32
Staphylococcus aureus 0.0051 1: 1024
Diplococcus pneumoniae 0.0106 1: 256
Escherichia coli (086B7) 0.0813 1: 32
Bacillus pyocyaneus 0.1625 1: 16
Bloodthirsty influenza bacterium 0.0813 1: 32
Experimental example 4 pyretic toxicity injection for curing are to the influence of mice specific humoral immunity
Adopt the chicken red blood cell immunization, choose 50 of healthy NIH mices, male and female half and half are divided into 5 groups.Grouping and administering mode are the same.Vein is got blood under the chicken wing, with normal saline Washed Red Blood Cells 3 times, makes 5% chicken erythrocyte suspension, and every mouse peritoneal injection 0.2ml carries out immunity, immunity administration after 2 days, and successive administration 5d, 7d plucks eyeball and gets blood.Get 20111 immune serums in clean tube, add the 2ml normal saline, and add 5% chicken red blood cell 0.5ml, it is standby to put into refrigerator.Other gets 2 of Cavia porcelluss, gets serum and makes 10% NS complement solution, gets its 0.5ml and adds in the refrigerated chicken red blood cell one immune serum test tube, reacts 30min in 37 ℃ of water-baths, takes out and puts into the frozen water cessation reaction, and is centrifugal, gets supernatant and surveys the OD value in the 540nm place.Experimental result proves that high, medium and low three the dosage groups of pyretic toxicity injection for curing all can obviously improve the hemolysin level of mice, with the analysis of matched group comparative statistics significant difference are arranged.Illustrate and be subjected to test product that there is potentiation in the humoral immunity of organism system.The results are shown in Table 5.
Table 5 pyretic toxicity injection for curing is to the influence of specific humoral immunity function (n=10, x ± s)
Group dosage (g/kg) OD value
Normal saline 0.1ml g/10g 0.0816 ± 0.0035
Pyretic toxicity injection for curing 20.30 0.1209 ± 0.0056**
10.15 0.0982±0.0053**
5.08 0.0947±0.0037**
Aspirin 0.5 0.1791 ± 0.0027**
* p<0.05, * * p<0.01 and the comparison of normal saline group.
The analgesic activity of experimental example 5 pyretic toxicity injection for curing
Get 50 of white mice, be divided into 5 groups at random, 10 every group: blank group, aspirin group, high, medium and low three the dosage groups of pyretic toxicity injection for curing.Each group is by the corresponding dosage intravenously administrable, and positive drug ig aspirin 0.2g/kg, 30 minutes lumbar injection 0.3% acetic acid after the administration, 0.2ml/ only observe each treated animal in 30 minutes and turn round the body number by what acetic acid brought out.Experiment shows, causes more persistent pain stimulation behind the mouse peritoneal injection acetic acid.Each group all has the pain reaction that reduces mice in various degree after the administration, and the analgesic activity of pyretic toxicity injection for curing high dose 10.15g/kg and aspirin group is remarkable, and animal is turned round the body number and obviously is less than matched group.
The analgesic activity of table 6 pyretic toxicity injection for curing (n=10, x ± s)
Group dosage (g/kg) is turned round the body number of times
Normal saline 24.3 ± 11.1
Pyretic toxicity injection for curing 20.30 12.5 ± 6.7*
10.15 16.2±7.3*
5.08 20.7±8.9
Aspirin 0.5 9.5 ± 7.2**
Compare with the normal saline group: * p<0.05, * * p<0.01
The following example all can be realized the effect of above-mentioned experimental example.
Embodiment 1:
Herba Artemisiae Annuae 1250g Flos Lonicerae 750g Fructus Gardeniae 600g
More than three flavors, Flos Lonicerae, Herba Artemisiae Annuae add 13-18 times of water gaging and soaked 3 hours, heating decocts distillation 2 times, each 2 hours, collect volatile oil simultaneously, standby.Merge decoction liquor, being evaporated to relative density is 1.03~1.08, and (it is 1.10~1.12 that ultrafiltrate is evaporated to 50 ℃ of relative densities to high speed centrifugation for 20000 commentaries on classics/min) get supernatant, classification ultrafiltration, and vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder.Fructus Gardeniae is ground into coarse powder, measures 80% alcohol heating reflux 1-3 time, each 1 hour with 6 times, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1: 1, transfers pH4.0 with hydrochloric acid, 100 ℃ were heated 1 hour, cold preservation 12 hours filters, and it is 1.10~1.12 that filtrate is concentrated into 50 ℃ of relative densities, vacuum drying gets Fructus Gardeniae in the cream powder.Get Herba Artemisiae Annuae and be, Flos Lonicerae volatile oil, add after 6g poloxamer 108 grinds mixings, add in the 900ml water for injection, stirring makes clear and bright, adds Flos Lonicerae, Herba Artemisiae Annuae dried cream powder again, stirs to make dissolving, transferring pH value with sodium hydroxide solution is 7.5~8.0, adds the injection water to 1000ml.Use G
4Sintered filter funnel filters, embedding in the 10ml ampoule, 100 ℃ of flowing steam sterilizations.Every 10ml, suitable crude drug 26 grams, intravenous drip, this product 10~20ml injection adds 5% must or 0.9% sodium chloride injection, 250~500ml, and quiet, every day 1 time or follow the doctor's advice.
Embodiment 2:
Herba Artemisiae Annuae 1100g Flos Lonicerae 800g Fructus Gardeniae 700g
More than three flavors, Flos Lonicerae, Herba Artemisiae Annuae add 13-18 times of water gaging and soaked 3 hours, heating decocts distillation 2 times, each 2 hours, collect volatile oil simultaneously, standby.Merge decoction liquor, being evaporated to relative density is 1.03~1.08, and high speed centrifugation (20000 commentaries on classics/min) get supernatant, being evaporated to 50 ℃ of relative densities is 1.10~1.12, vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder.Fructus Gardeniae is ground into coarse powder, measures 80% alcohol heating reflux 1-3 time, each 1 hour with 6 times, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1: 1, transfers pH4.0 with hydrochloric acid, 100 ℃ were heated 1 hour, cold preservation 12 hours filters, and it is 1.10~1.12 that filtrate is concentrated into 50 ℃ of relative densities, vacuum drying gets the Fructus Gardeniae dried cream powder.Get volatile oil and dried cream powder, add the edible vegetable oil of 0.5~1.5 times of amount, grind, be pressed into 1000 of soft capsules through conventional technology, promptly get the soft capsule of compositions, every dress 0.55g is equivalent to crude drug 2.6g.Each 1-2 grain, 2-3 time/day.
Embodiment 3This composite injection method of quality control:
Differentiate: a. gets this composite injection 5ml, is equivalent to crude drug 13g, adds 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Extracting honeysuckle control medicinal material 0.5g adds water 20ml and refluxed 1 hour in addition, filters, and filtrate adds n-butyl alcohol according to supplying the brilliant solution manufacturing method preparation of examination, medical material solution in contrast; Get the chlorogenic acid reference substance again, add methanol and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography (" appendix VIB of Chinese pharmacopoeia nineteen ninety-five version) test, draw each 4 μ l of above-mentioned three kinds of solution, put respectively on same silica gel H plate, with 8.5: 1: 0.5 ethyl acetate-formic acid-water was developing solvent, launched, and took out, dry, inspection is known under ultra-violet lamp 365nm; In the test sample chromatograph, respectively with Flos Lonicerae control medicinal material and the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color;
B. get this composite injection 5ml, be equivalent to crude drug 13g, add water saturated n-butyl alcohol collection and drive 2 times, each 10ml merges n-butyl alcohol liquid, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Fructus Gardeniae control medicinal material 1g, adds water 20ml and refluxes 1 hour, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the gardenoside reference substance again, add methanol and make the solution that every 1ml contains 4mg, in contrast product solution; According to thin layer chromatography (" appendix vIB of Chinese pharmacopoeia nineteen ninety-five version) test, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same high-efficient silica gel GF254 lamellae, with 7: 3: 2: 0.2 chloroform-acetonitrile-methanol-strong aqua ammonia was developing solvent, launch, take out, dry, inspection is known under ultra-violet lamp 254nm; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle; With the corresponding position of Fructus Gardeniae control medicinal material chromatograph on, show the speckle of same color;
C. get this composite injection 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast; According to thin layer chromatography (appendix VIB of (Chinese Pharmacopoeia) nineteen ninety-five version) test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel G thin plate, with 8: 2: 2: 0.2 chloroform-acetonitrile-methanol-strong aqua ammonia was developing solvent, launched, and took out, dry, inspection is known under ultra-violet lamp 365nm; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
Assay: a. Fructus Gardeniae salidroside content is measured, the photograph high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia nineteen ninety-five version) measure; Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica, and the 0.05mol/L sodium hydrogen phosphate is transferred pH6.0 with phosphoric acid, and 88: 12 sodium hydrogen phosphate-acetonitriles are mobile phase; Detect wavelength 237nm, theoretical tower; The plate number calculates by the gardenoside peak should be not less than 2500; The preparation of reference substance solution, precision take by weighing gardenoside reference substance 6mg, put in the 100ml measuring bottle, add the dissolving of 50% methanol aqueous solution and are diluted to scale, shake up, promptly; This composite preparation solution 1ml is measured in the preparation of need testing solution, precision, is equivalent to crude drug 2.6g, puts in the 100ml measuring bottle, add 50% methanol aqueous solution and be diluted to scale, shake up, precision is got 5ml again, puts in the 10ml measuring bottle, add 50% methanol aqueous solution to scale, shake up, as need testing solution; Algoscopy, precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly.
This composite preparation solution 1ml is equivalent to crude drug 2.6g, contains Fructus Gardeniae with gardenoside (C
17H
24O
11) meter, should be 9.0mg-14g0mg;
B. determination of chlorogenic acid, measure according to high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia nineteen ninety-five version), chromatographic condition and system suitability test, with octadecylsilane chemically bonded silica is filler, 80: 20 aqueous acetic acid-methanol of 1% are mobile phase, the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid honeybee should be not less than 3000; The preparation of reference substance solution, precision take by weighing chlorogenic acid reference substance 6mg, put in the 100ml measuring bottle, add 1: 1 aqueous acetic acid-dissolve with methanol of 1% and are diluted to scale, shake up, promptly; This compositions ejection preparation 1mL is measured in the preparation of need testing solution, precision, puts in the 100ml measuring bottle, adds 1%1: 1 aqueous acetic acid-dissolve with methanol and is diluted to scale, shakes up, promptly; Algoscopy, precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.
This product formulation soln 1ml is equivalent to crude drug 2.6g, contains Flos Lonicerae with chlorogenic acid (C
16H
18O
4) meter, should be 6.4mg~9.6mg.
Check:
The n-butyl alcohol determination of residual amount: by " Chinese pharmacopoeia appendix gas chromatography of version in 2000 and alcohol determining method are measured; Chromatographic condition and system suitability test, chromatographic column: SUPELCO company: SLMPLICLTY-WAX capillary quartz column (30m * 530 μ m * 1.0 μ m) chromatographic condition: carrier gas: N
2, shunt mode sample introduction not, injector temperature: 200 ℃, constant voltage mode: the average linear speed of pressure 10Kpa is 14cm/sec; Column temperature: 80 ℃ kept 1.5 minutes, rose to 120 ℃ with 5 ℃/min again, rose to 200 ℃ with 20 ℃/min again, kept 10 minutes; Number of theoretical plate calculates by the ethanol peak should be not less than 1500;
Reference substance solution preparation: precision is measured n-butyl alcohol 0.1ml and is put in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, and precision is measured 0.1ml, puts in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, as n-butyl alcohol contrast liquid;
Standard curve is drawn, accurate n-butyl alcohol contrast liquid 1 μ l, 2 μ l, 3 μ l, 4 μ l, the inject gas chromatograph drawn, record chromatographic peak trap integrated value is an abscissa with reference substance concentration, is vertical coordinate with the trap score value, the drawing standard curve gets the n-butyl alcohol standard curve;
The need testing solution preparation: get 1 bottle of this combination injection, inclining injection, puts in the conical flask, shakes up, as need testing solution;
Algoscopy: the accurate need testing solution 1 μ l that draws, inject gas chromatograph, record test sample chromatographic peak trap integrated value, the substitution standard curve calculates content; This combination injection contains n-butyl alcohol must not cross 10/1000000ths.
Embodiment 4:The preparation of composition material medicine intermediate
Flos Lonicerae, the preparation of Herba Artemisiae Annuae dried cream powder: extracting honeysuckle 750g extracting in water secondary (90 ℃), (amount of water was 15 times in each one hour, 10 times), extracting solution is put in addition, after getting Herba Artemisiae Annuae 1250g and adding 4 times of water gagings and run through, vapor distillation extracted volatile oil in 6 hours, volatile oil is put in addition, extracts Flos Lonicerae and Herba Artemisiae Annuae extracting solution, filters, being evaporated to relative density is 1.10 (60 ℃), add ethanol and make that to contain the alcohol amount be 75%, left standstill 24 hours, filter, it is 1.20 (60 ℃) that filtrate decompression is concentrated into relative density, transferring pH value with hydrochloric acid is about 2.0, uses equivalent ethyl acetate extraction 10 times, gets extract, be evaporated to no ethyl acetate flavor, inclining concentrated solution, and vacuum drying gets Flos Lonicerae, the Herba Artemisiae Annuae dried cream powder.
The preparation of Fructus Gardeniae dried cream powder: Fructus Gardeniae 600g was ground into coarse powder, with 6 times of amount 80% alcohol heating reflux secondaries, each 1 hour, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1: 1, transfer pH3.0 with hydrochloric acid, 100 ℃ were heated 1 hour, added the hard paraffin of 1% medical material amount, stir evenly, cold preservation 12 hours filters, the n-butanol extraction of filtrate usefulness equivalent 6 times, concentrating under reduced pressure is to no n-butyl alcohol flavor, and vacuum drying gets the Fructus Gardeniae dried cream powder.
Embodiment 5:The method of quality control of composition material medicine intermediate (described intermediate is prepared with embodiment 4 methods)
One, the quality standard of Herba Artemisiae Annuae, Flos Lonicerae intermediate:
This product 1g is got in [discriminating] (1), adds dissolve with methanol, filters, and is settled to 10ml, as need testing solution.Other gets the chlorogenic acid reference substance, adds methanol and makes the solution that every 1ml contains 2mg, in contrast product solution.According to thin layer chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 B) test, draw each 4 μ l of above-mentioned two kinds of solution, put respectively on same silica gel H plate, with ethyl acetate-formic acid-water (8.5: 1: 0.5) is developing solvent, launches, and takes out, dry, inspection is known under ultra-violet lamp 365nm.In the test sample chromatograph, with the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color.
(2) get [discriminating] (1) following need testing solution as need testing solution.Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast.According to thin layer chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 B) test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel G thin plate, with chloroform-acetonitrile-methanol-strong aqua ammonia (8: 2: 2: 0.2) be developing solvent, launch, take out, dry, inspection is known under ultra-violet lamp 365nm.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
[assay]
Determination of chlorogenic acid: the photograph high performance liquid chromatography (" an appendix VI of Chinese pharmacopoeia nineteen ninety-five version D) measure.
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler, and 1% aqueous acetic acid-methanol (80: 20) is a mobile phase, and the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid peak should be not less than 3000.
The preparation of reference substance solution: precision takes by weighing chlorogenic acid reference substance 6mg, puts in the 100ml measuring bottle, adds 1% aqueous acetic acid-methanol (1: 1) and dissolves and be diluted to scale, shakes up, promptly.
The preparation of need testing solution: precision is measured this product 0.1g, puts in the 100ml measuring bottle, adds dissolve with methanol and is diluted to scale, and the accurate 1ml that draws puts in the 5ml measuring bottle, adds 1% aqueous acetic acid-methanol (1: 1) and dissolves and be diluted to scale, shakes up, promptly.Algoscopy: precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.Herba Artemisiae Annuae, Flos Lonicerae intermediate contain chlorogenic acid (C
16H
18O
4), should be 12~25%.
Two, Fructus Gardeniae dried cream powder method of quality control
[discriminating] gets this product 1g, adds dissolve with methanol, filters, and is settled to 10ml, as need testing solution.Other gets the gardenoside reference substance, adds methanol and makes the solution that every 1ml contains 4mg, in contrast product solution.According to thin layer chromatography (" an appendix VI of Chinese pharmacopoeia version in 2000 B) test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively in same high-efficient silica gel GF
254On the lamellae, (7: 3: 2: 0.2) be developing solvent, launch that taking-up is dried, inspection was known under ultra-violet lamp 254nm with chloroform-acetonitrile-methanol one strong aqua ammonia.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle.
[assay]
The gardenoside assay: high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia nineteen ninety-five version) measure.
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler, and 0.05mol/L sodium hydrogen phosphate (transferring pH6.0 with phosphoric acid)-acetonitrile (88: 12) is a mobile phase; Detect wavelength 237nm.Theoretical cam curve is calculated by the gardenoside peak should be not less than 2500.
The preparation of reference substance solution: it is an amount of that precision takes by weighing the gardenoside reference substance, adds the solution dissolving of methanol-water (1: 1), is prepared into the solution that every 1ml contains 0.06mg approximately, shakes up, promptly.
The preparation of need testing solution: precision is measured this product 0.1g, puts in the 100ml measuring bottle, adds 50% methanol aqueous solution and is diluted to scale, shakes up, and precision is got 1ml again, puts in the 10ml measuring bottle, adds 50% methanol aqueous solution to scale, shakes up, as need testing solution.
Algoscopy: precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly.Contain gardenoside (C in the Fructus Gardeniae intermediate
17H
24O
11), should be 25~40%.
Embodiment 6
Get the Herba Artemisiae Annuae of embodiment 4 preparations, Flos Lonicerae intermediate and Fructus Gardeniae intermediate add injection water 1000ml, boil, drop into above-mentioned two intermediate, stir evenly, seethe with excitement after 4 minutes, be cooled to room temperature, cold preservation 24 hours filters, it is 2-3 that filtrate is transferred PH, adds 1% active carbon, boils 10 minutes, 24 hours after-filtration of cold preservation, filtrate is heated to boiling, transferring PH in the heating process is 5.05, the about 10 minutes cool to room temperature that seethe with excitement, cold preservation 48 hours, filter, add the 0.5g sodium sulfite, standardize solution stirs and gets solution 50ml to 1000ml, be heated to 65 ℃ and add tween 80 4ml, stir evenly, add volatile oil, stir evenly, (molecular weight is 30,000 to filter ultrafiltration, 10,000), cross the microporous filter membrane of 0.22 μ m, packing, flowing steam sterilization 45min.
Claims (19)
1, a kind of Chinese medicine compositions with analgesic, antiviral, antibacterial action is characterized in that this pharmaceutical composition made by following raw material medicaments:
Herba Artemisiae Annuae 1000-1400 weight portion Flos Lonicerae 600-900 weight portion
Fructus Gardeniae 500-700 weight portion.
2, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following raw material medicaments:
Herba Artemisiae Annuae 1250 weight portion Flos Loniceraes 750 weight portion Fructus Gardeniaes 600 weight portions.
3, pharmaceutical composition as claimed in claim 1 is characterized in that this pharmaceutical composition made by following raw material medicaments:
Herba Artemisiae Annuae 1100 weight portion Flos Loniceraes 800 weight portion Fructus Gardeniaes 700 weight portions.
4,, it is characterized in that this pharmaceutical composition also can add excipient and make tablet, oral liquid, capsule, granule, ejection preparation as claim 1,2 or 3 described pharmaceutical compositions.
5, the preparation method of drug combination preparation as claimed in claim 4 can at first prepare the intermediate of crude drug, adds acceptable accessories again and makes, and it is characterized in that the crude drug intermediates preparation may further comprise the steps:
A. the preparation of Flos Lonicerae, Herba Artemisiae Annuae dried cream powder: Flos Lonicerae extracting in water 1-3 time, 80-100 ℃, each 1-2 hour, amount of water was 9-16 times, extracting solution is put in addition; After Herba Artemisiae Annuae adds 3-6 times of water gaging and runs through, extracted volatile oil in vapor distillation 5-8 hour, volatile oil is put in addition, extract Flos Lonicerae and Herba Artemisiae Annuae extracting solution, filter, being evaporated to 60 ℃ of relative densities is 1.10, adds ethanol and makes and contain the alcohol amount and be 70-80%, left standstill 20-36 hour, filter, it is 1.20 that filtrate decompression is concentrated into 60 ℃ of relative densities, and transferring pH value with hydrochloric acid is about 1.8-2.3, with equivalent ethyl acetate extraction 9-12 time, get extract, be evaporated to no ethyl acetate flavor, inclining concentrated solution, vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder;
B. the preparation of Fructus Gardeniae dried cream powder: Fructus Gardeniae is ground into coarse powder, doubly measures the 70-90% alcohol heating reflux 1-3 time with 5-8, each 1-2 hour, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1:1, transferring Ph with hydrochloric acid is 2.5-3.5, and 100 ℃ were heated 1-2 hour, added the hard paraffin of 1% medical material amount, stir evenly, cold preservation 10-14 hour, filter, the n-butanol extraction of filtrate usefulness equivalent 5-7 time, concentrating under reduced pressure is to no n-butyl alcohol flavor, and vacuum drying gets the Fructus Gardeniae dried cream powder.
6, the preparation method of drug combination preparation as claimed in claim 5, it is characterized in that the crude drug intermediate that makes carries out assay with high performance liquid chromatography: Herba Artemisiae Annuae, Flos Lonicerae intermediate contain chlorogenic acid, should be 12~25%; Contain gardenoside in the Fructus Gardeniae intermediate, should be 25~40%.
7, as the preparation method of the described drug combination preparation of claim 5-6, it is characterized in that the preparation method of injection is: get water for injection 800-1200 parts by volume and boil, drop into and make two intermediate, stir evenly, seethe with excitement after 3-7 minute, be cooled to room temperature, cold preservation 20-36 hour, filter, it is 2-3 that filtrate is transferred PH, adds 1% active carbon, boiled 8-14 minute, cold preservation 20-36 hour after-filtration, filtrate is heated to boiling, transferring PH in the heating process is 5.05, the 9-13 minute cool to room temperature that seethe with excitement cold preservation 40-58 hour, filters, add 0.3-0.8 weight portion sodium sulfite, standardize solution 1000 parts by volume stir and get solution 50 parts by volume, are heated to 65 ℃ and add tween 80 3-5 parts by volume, stir evenly, add volatile oil, stir evenly, filter ultrafiltration, molecular weight is 30,000,10,000, cross the microporous filter membrane of 0.22 μ m, packing, flowing steam sterilization 35-50min.
8, preparation of drug combination method as claimed in claim 4 is characterized in that this method is: Flos Lonicerae, Herba Artemisiae Annuae add 13-18 times of water gaging and soaked 2-4 hour, and heating decocts distillation 1-3 time, and each 1-3 hour, collect volatile oil simultaneously, standby; Merge decoction liquor, being evaporated to relative density is 1.03~1.08, and high speed centrifugation is got supernatant, the classification ultrafiltration, and it is 1.08~1.15 that ultrafiltrate is evaporated to 40-60 ℃ of relative density, vacuum drying gets Flos Lonicerae, Herba Artemisiae Annuae dried cream powder; Fructus Gardeniae is ground into coarse powder, doubly measures the 60-85% alcohol heating reflux 1-3 time with 5-7, and each 1-2 hour, merge medicinal liquid, filter, filtrate recycling ethanol also is concentrated into 1-2: 1-2, transfer pH4.0 with hydrochloric acid, 100.℃ heating 0.5-1.5 hour, cold preservation 10-14 hour, filter, it is 1.10~1.12 that filtrate is concentrated into 45-55 ℃ of relative density, vacuum drying, the Fructus Gardeniae dried cream powder; Get Herba Artemisiae Annuae, Flos Lonicerae volatile oil usefulness adjuvant behind the routine parcel,, make tablet, oral liquid, capsule, granule, ejection preparation with above-mentioned dried cream powder mixing.
9, preparation of drug combination method as claimed in claim 8, the preparation method that it is characterized in that injection is: get Herba Artemisiae Annuae, Flos Lonicerae volatile oil, after adding 5-7 weight portion poloxamer 108 grinding mixings, add in the 900 parts by volume waters for injection, stirring makes clear and bright, adds Flos Lonicerae in the above-mentioned technology, Herba Artemisiae Annuae dried cream powder again, and the Fructus Gardeniae dried cream powder stirs and makes dissolving, transferring pH value with sodium hydroxide solution is 7.5~8.0, adds injection water to 1000 parts by volume; Filter, embedding, sterilization promptly gets injection.
10, preparation of drug combination method as claimed in claim 9 is characterized in that can also making lyophilized injectable powder by freeze-drying in embedding, sterilization back in the preparation method of injection.
11, preparation of drug combination method as claimed in claim 10 is characterized in that adding Flos Lonicerae, Herba Artemisiae Annuae dried cream powder in the preparation method of injection in water for injection, during the Fructus Gardeniae dried cream powder, adds 0.2~5 times caffolding agent of total dried cream powder again.
12, preparation of drug combination method as claimed in claim 11, the preparation method medium-height trestle agent that it is characterized in that injection is glucose or mannitol or sodium chloride.
13, require the method for quality control of 1,2 or 3 described pharmaceutical composition ejection preparations as profit, it is characterized in that discrimination method in this method comprises one or more in the following discriminating:
A. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 1-3 time, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Extracting honeysuckle control medicinal material 0.5g adds water 20ml backflow 0.5-1.5 hour in addition, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the chlorogenic acid reference substance again, add methanol and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography test, draw each 4 μ l of above-mentioned three kinds of solution, put respectively on same silica gel H plate, with 8-9: 0.5-1.5: 0.5 ethyl acetate-formic acid-water is developing solvent, launches, and takes out, and dries, and inspection is known under ultra-violet lamp; In the test sample chromatograph, respectively with Flos Lonicerae control medicinal material and the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color;
B. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add water saturated n-butyl alcohol collection and drive 1-3 time, each 10ml merges n-butyl alcohol liquid, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Fructus Gardeniae control medicinal material 1g, adds water 15-25ml and refluxes 1 hour, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the gardenoside reference substance again, add methanol and make the solution that every 1ml contains 4mg, in contrast product solution; According to the thin layer chromatography test, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same-high-efficient silica gel GF254 lamellae, with 6-8: 2-4: 1-3: 0.1-0.3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launches, and takes out, dry, inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle; With the corresponding position of Fructus Gardeniae control medicinal material chromatograph on, show the speckle of same color;
C. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast; According to thin layer chromatography test, draw each 5 μ 1 of above-mentioned two kinds of solution, put respectively in on-silica gel G the thin plate, with 7-9: 1-3: 1-3: 0.1-3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launches, and takes out, and dries, and inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
14, require the method for quality control of 13 described pharmaceutical compositions as profit, its feature comprises one or more of following discriminating at the discrimination method that is used for injection:
A. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Extracting honeysuckle control medicinal material 0.5g adds water 20ml and refluxed 1 hour in addition, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the chlorogenic acid reference substance again, add methanol and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography test, draw each 4 μ l of above-mentioned three kinds of solution, put respectively in on-silica gel H the plate, be developing solvent with 8.5: 1: 0.5 ethyl acetate-formic acid-water, launch, take out, dry, inspection is known under ultra-violet lamp 365nm; In the test sample chromatograph, respectively with Flos Lonicerae control medicinal material and the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color;
B. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add water saturated n-butyl alcohol collection and drive 2 times, each 10ml merges n-butyl alcohol liquid, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Fructus Gardeniae control medicinal material 1g, adds water 20ml and refluxes 1 hour, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the gardenoside reference substance again, add methanol and make the solution that every 1ml contains 4mg, in contrast product solution; According to thin layer chromatography test, draw each 5 μ l of above-mentioned three kinds of solution, put respectively in on-high-efficient silica gel GF254 the lamellae, with 7: 3: 2: 0.2 chloroform-acetonitrile-methanol-strong aqua ammonia was developing solvent, launched, and took out, and dried, inspection is known under ultra-violet lamp 254nm; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle; With the corresponding position of Fructus Gardeniae control medicinal material chromatograph on, show the speckle of same color;
C. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast; According to thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively in on-silica gel G the thin plate, with 8: 2: 2: 0.2 chloroform-acetonitrile-methanol-strong aqua ammonia was developing solvent, launched, and took out, and dried, inspection is known under ultra-violet lamp 365nm; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color.
15, require the method for quality control of 1,2 or 3 described pharmaceutical compositions as profit, it is characterized in that assay in this method comprises one or more in the following content assaying method:
A. the Fructus Gardeniae salidroside content is measured, according to high effective liquid chromatography for measuring; Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica, and the 0.05mol/L sodium hydrogen phosphate is transferred pH6.0 with phosphoric acid, 80-90: 10-14 sodium hydrogen phosphate-acetonitrile is a mobile phase; Detect wavelength 237nm, theoretical tower; The plate number calculates by the gardenoside peak should be not less than 2500; The preparation of reference substance solution, precision take by weighing gardenoside reference substance 6mg, put in the 100ml measuring bottle, add the dissolving of 40-60% methanol aqueous solution and are diluted to scale, shake up, promptly; The preparation of need testing solution, precision is measured this composite preparation solution 1ml, be equivalent to crude drug 2.6g, put in the 100ml measuring bottle, add the 40-60% methanol aqueous solution and be diluted to scale, shake up, precision is got 5ml again, puts in the 10ml measuring bottle, adds the 40-60% methanol aqueous solution to scale, shake up, as need testing solution; Algoscopy, precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly;
B. determination of chlorogenic acid, according to high effective liquid chromatography for measuring, chromatographic condition and system suitability test, with octadecylsilane chemically bonded silica is filler, 1% 75-85: 15-25 aqueous acetic acid-methanol is mobile phase, the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid honeybee should be not less than 3000; The preparation of reference substance solution, precision take by weighing chlorogenic acid reference substance 6mg, put in the 100ml measuring bottle, add 1%0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; This composite preparation oral liquid 1mL is measured in the preparation of need testing solution, precision, puts in the 100ml measuring bottle, adds 1%0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; Algoscopy, precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.
16, require the method for quality control of 12 described pharmaceutical compositions as profit, its feature comprises one or more of following content assaying method at the assay that is used for injection:
A. the Fructus Gardeniae salidroside content is measured, according to high effective liquid chromatography for measuring; Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica, and the 0.05mol/L sodium hydrogen phosphate is transferred pH6.0 with phosphoric acid, and 88: 12 sodium hydrogen phosphate-acetonitriles are mobile phase; Detect wavelength 237nm, theoretical tower; The plate number calculates by the gardenoside peak should be not less than 2500; The preparation of reference substance solution, precision take by weighing gardenoside reference substance 6mg, put in the 100ml measuring bottle, add the dissolving of 50% methanol aqueous solution and are diluted to scale, shake up, promptly; This composite preparation solution 1ml is measured in the preparation of need testing solution, precision, is equivalent to crude drug 2.6g, puts in the 100ml measuring bottle, add 50% methanol aqueous solution and be diluted to scale, shake up, precision is got 5ml again, puts in the 10ml measuring bottle, add 50% methanol aqueous solution to scale, shake up, as need testing solution; Algoscopy, precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly;
B. determination of chlorogenic acid, according to high effective liquid chromatography for measuring, chromatographic condition and system suitability test, with octadecylsilane chemically bonded silica is filler, 80: 20 aqueous acetic acid-methanol of 1% are mobile phase, the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid honeybee should be not less than 3000; The preparation of reference substance solution, precision take by weighing chlorogenic acid reference substance 6mg, put in the 100ml measuring bottle, add 1%1: 1 aqueous acetic acid-dissolve with methanol and are diluted to scale, shake up, promptly; This composite preparation solution 1mL is measured in the preparation of need testing solution, precision, is equivalent to crude drug 2.6g, puts in the 100ml measuring bottle, adds 1%1: 1 aqueous acetic acid-dissolve with methanol and is diluted to scale, shakes up, promptly; Algoscopy, precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.
17, the method for quality control as claim 1,2 or 3 described pharmaceutical compositions comprises the steps:
Differentiate: a. gets this composite preparation solution 5ml, is equivalent to crude drug 13g, adds 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 1-3 time, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Extracting honeysuckle control medicinal material 0.5g adds water 20ml backflow 0.5-1.5 hour in addition, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the chlorogenic acid reference substance again, add methanol and make the solution that every 1ml contains 2mg, in contrast product solution; According to thin layer chromatography test, draw each 4 μ l of above-mentioned three kinds of solution, put respectively in on-silica gel H the plate, with 8-9: 0.5-1.5: 0.5 ethyl acetate-formic acid-water is developing solvent, launches, and takes out, and dries, and inspection is known under ultra-violet lamp; In the test sample chromatograph, respectively with Flos Lonicerae control medicinal material and the corresponding position of chlorogenic acid reference substance chromatograph on, show the speckle of same color; B. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add water saturated n-butyl alcohol collection and drive 1-3 time, each 10ml merges n-butyl alcohol liquid, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Fructus Gardeniae control medicinal material 1g, adds water 15-25ml and refluxes 1 hour, filters, and filtrate adds n-butyl alcohol according to the preparation of need testing solution preparation method, medical material solution in contrast; Get the gardenoside reference substance again, add methanol and make the solution that every 1ml contains 4mg, in contrast product solution; According to the thin layer chromatography test, draw each 5 μ l of above-mentioned three kinds of solution, put respectively on same-high-efficient silica gel GF254 lamellae, with 6-8: 2-4: 1-3: 0.1-0.3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launches, and takes out, dry, inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical color speckle; With the corresponding position of Fructus Gardeniae control medicinal material chromatograph on, show the speckle of same color;
C. get this composite preparation solution 5ml, be equivalent to crude drug 13g, add 1%H
2SO
4Aqueous solution adjust pH 3 adds water saturated n-butanol extraction 2 times, and each 10ml merges butanol solution, and water-bath volatilizes, and residue adds methanol 5ml dissolving, as need testing solution; Other gets Herba Artemisiae Annuae control medicinal material 2g, adds water 20ml, and supersound extraction 1h filters, and filtrate adds the preparation method preparation of n-butyl alcohol according to need testing solution, medical material solution in contrast; According to thin layer chromatography test, draw each 5 μ l of above-mentioned two kinds of solution, put respectively in on-silica gel G the thin plate, with 7-9: 1-3: 1-3: 0.1-3 chloroform-acetonitrile-methanol-strong aqua ammonia is developing solvent, launches, and takes out, and dries, and inspection is known under ultra-violet lamp; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the fluorescence speckle of same color;
The n-butyl alcohol determination of residual amount: gas chromatography and alcohol determining method are measured; Chromatographic condition and system suitability test, chromatographic column: SUPELCO company: SLMPLICLTY-WAX capillary quartz column 30m * 530 μ m * 1.0 μ m, chromatographic condition: carrier gas: N
2, shunt mode sample introduction not, injector temperature: 200 ℃, constant voltage mode: the average linear speed of pressure 10Kpa is 14cm/sec; Column temperature: 80 ℃ kept 1.5 minutes, rose to 120 ℃ with 5 ℃/min again, rose to 200 ℃ with 20 ℃/min again, kept 10 minutes; Number of theoretical plate calculates by the ethanol peak should be not less than 1500;
Reference substance solution preparation: precision is measured n-butyl alcohol 0.1ml and is put in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, and precision is measured 0.1ml, puts in the 100ml measuring bottle, adds ethanol dilution to scale, shakes up, as n-butyl alcohol contrast liquid;
Standard curve is drawn, accurate n-butyl alcohol contrast liquid 1 μ l, 2 μ l, 3 μ l, 4 μ l, the inject gas chromatograph drawn, record chromatographic peak trap integrated value is an abscissa with reference substance concentration, is vertical coordinate with the trap score value, the drawing standard curve gets the n-butyl alcohol standard curve;
The need testing solution preparation: get 1 bottle of this combination injection, inclining injection, puts in the conical flask, shakes up, as need testing solution;
Algoscopy: the accurate need testing solution 1 μ l that draws, inject gas chromatograph, record test sample chromatographic peak trap integrated value, the substitution standard curve calculates content; This combination injection contains n-butyl alcohol must not cross 10/1000000ths.
Assay: a. Fructus Gardeniae salidroside content is measured, according to high effective liquid chromatography for measuring; Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica, and the 0.05mol/L sodium hydrogen phosphate is transferred pH6.0 with phosphoric acid, 80-90: 10-14 sodium hydrogen phosphate-acetonitrile is a mobile phase; Detect wavelength 237nm, theoretical tower; The plate number calculates by the gardenoside peak should be not less than 2500; The preparation of reference substance solution, precision take by weighing gardenoside reference substance 6mg, put in the 100ml measuring bottle, add the dissolving of 40-60% methanol aqueous solution and are diluted to scale, shake up, promptly; The preparation of need testing solution, precision is measured this composite preparation solution 1ml, be equivalent to crude drug 2.6g, put in the 100ml measuring bottle, add the 40-60% methanol aqueous solution and be diluted to scale, shake up, precision is got 5ml again, puts in the 10ml measuring bottle, adds the 40-60% methanol aqueous solution to scale, shake up, as need testing solution; Algoscopy, precision is measured reference substance solution and each 10 μ l of offerings solution respectively, injects chromatograph of liquid, measures, and calculates promptly;
B. determination of chlorogenic acid, according to high effective liquid chromatography for measuring, chromatographic condition and system suitability test, with octadecylsilane chemically bonded silica is filler, 1% 75-85: 15-25 aqueous acetic acid-methanol is mobile phase, the detection wavelength is 327nm, and theoretical cam curve is calculated by the chlorogenic acid honeybee should be not less than 3000; The preparation of reference substance solution, precision take by weighing chlorogenic acid reference substance 6mg, put in the 100ml measuring bottle, add 1% 0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; This composite preparation solution 1mL is measured in the preparation of need testing solution, precision, is equivalent to crude drug 2.6g, puts in the 100ml measuring bottle, adds 1%0.5-1.5: 0.5-1.5 aqueous acetic acid-dissolve with methanol also is diluted to scale, shakes up, promptly; Algoscopy, precision is measured reference substance solution and each 10 μ l of need testing solution respectively, injects chromatograph of liquid, measures, and calculates, promptly.
18, has application in the medicine of analgesic, antiviral, antibacterial action as claim 1,2 or 3 described pharmaceutical compositions in preparation.
19, as claim 1, the application of 2 or 3 described pharmaceutical compositions in preparing treatment virus and bacterial upper respiratory tract infection, influenza, acute/chronic bronchitis, pneumonia medicine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410000134 CN1269498C (en) | 2003-01-08 | 2004-01-06 | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03100045 | 2003-01-08 | ||
CN03100045.2 | 2003-01-08 | ||
CN 200410000134 CN1269498C (en) | 2003-01-08 | 2004-01-06 | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100790388A Division CN100534465C (en) | 2003-01-08 | 2004-01-06 | A Chinese medicinal composition, preparation method and quality control method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1517124A true CN1517124A (en) | 2004-08-04 |
CN1269498C CN1269498C (en) | 2006-08-16 |
Family
ID=34314697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410000134 Expired - Lifetime CN1269498C (en) | 2003-01-08 | 2004-01-06 | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1269498C (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100400059C (en) * | 2004-12-17 | 2008-07-09 | 江苏康缘药业股份有限公司 | Method for identifying finger print atlas of injecta |
CN101721515B (en) * | 2008-10-28 | 2012-10-03 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparing medicine for treating hand, mouth and foot diseases |
CN101773238B (en) * | 2010-02-02 | 2012-11-07 | 华南农业大学 | Application of artemisia apiacea extract |
CN105687401A (en) * | 2014-11-25 | 2016-06-22 | 哈药集团中药二厂 | Traditional Chinese medicine composition comprising sweet wormwood, cape jasmine and honeysuckle and method for preparation of nasal cavity washing agent from traditional Chinese medicine composition |
CN107875215A (en) * | 2017-12-14 | 2018-04-06 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition for anaemia |
CN108434219A (en) * | 2018-06-12 | 2018-08-24 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition is preparing the application in treating or preventing tympanitis drug |
CN109430645A (en) * | 2018-11-15 | 2019-03-08 | 湖北大别山药业股份有限公司 | A kind of novel honeysuckle compound beverage and preparation method thereof |
CN113288943A (en) * | 2020-02-21 | 2021-08-24 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection |
WO2022022020A1 (en) * | 2020-07-30 | 2022-02-03 | 江苏康缘药业股份有限公司 | Traditional chinese medicine composition, preparation method and use |
-
2004
- 2004-01-06 CN CN 200410000134 patent/CN1269498C/en not_active Expired - Lifetime
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100400059C (en) * | 2004-12-17 | 2008-07-09 | 江苏康缘药业股份有限公司 | Method for identifying finger print atlas of injecta |
CN101721515B (en) * | 2008-10-28 | 2012-10-03 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparing medicine for treating hand, mouth and foot diseases |
CN101773238B (en) * | 2010-02-02 | 2012-11-07 | 华南农业大学 | Application of artemisia apiacea extract |
CN105687401A (en) * | 2014-11-25 | 2016-06-22 | 哈药集团中药二厂 | Traditional Chinese medicine composition comprising sweet wormwood, cape jasmine and honeysuckle and method for preparation of nasal cavity washing agent from traditional Chinese medicine composition |
CN107875215A (en) * | 2017-12-14 | 2018-04-06 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition for anaemia |
CN107875215B (en) * | 2017-12-14 | 2021-02-19 | 江苏康缘药业股份有限公司 | Traditional Chinese medicine composition for treating anemia |
CN108434219A (en) * | 2018-06-12 | 2018-08-24 | 江苏康缘药业股份有限公司 | A kind of Chinese medicine composition is preparing the application in treating or preventing tympanitis drug |
CN109430645A (en) * | 2018-11-15 | 2019-03-08 | 湖北大别山药业股份有限公司 | A kind of novel honeysuckle compound beverage and preparation method thereof |
CN113288943A (en) * | 2020-02-21 | 2021-08-24 | 江苏康缘药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection |
WO2021164401A1 (en) * | 2020-02-21 | 2021-08-26 | 江苏康缘药业股份有限公司 | Use of traditional chinese medicine composition in preparation of drugs for treating or preventing coronavirus infection |
WO2022022020A1 (en) * | 2020-07-30 | 2022-02-03 | 江苏康缘药业股份有限公司 | Traditional chinese medicine composition, preparation method and use |
CN114053343A (en) * | 2020-07-30 | 2022-02-18 | 江苏康缘药业股份有限公司 | Traditional Chinese medicine composition, preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
CN1269498C (en) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8586108B2 (en) | Extracts of Chenopodium ambrosioides L., the compositions comprising said extracts, the preparing process and application thereof | |
CN1269498C (en) | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method | |
CN1876045A (en) | A Chinese medicinal composition, its preparation process and quality control method | |
CN1405314A (en) | Cryptoporus volvatus fermented product, and its preparation method and application | |
CN1313109C (en) | Decoction preparation of semen sinapis albae, fructus perillae and semen raphani and its preparing method | |
CN103495162B (en) | Preparation method of porcine reproductive and respiratory syndrome compound inactivated vaccine | |
CN1506092A (en) | Elsholizia extract capsule for treating diarrhea and its prepn | |
CN1267110C (en) | Elsholizia extract prepn and its quality control method and new use | |
CN1466951A (en) | Gardenoside general extracts preparation and making method and uses | |
CN1915986A (en) | High purified tanshinone IIA sodium sulfonate, fabricating method, and preparation | |
CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof | |
CN113288943A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing coronavirus infection | |
CN1506094A (en) | Elsholizia extract granule for treating diarrhea and its prepn | |
CN117224670B (en) | Liposome adjuvant composition, vaccine composition, and preparation methods and applications thereof | |
CN1301099C (en) | Earthworm drip pill and its preparation method | |
CN1301100C (en) | Nauclea officinalis drip pill and its preparation method | |
CN1301107C (en) | Xiyanping drop pills of possessing function of clearing away heat and toxic materia and preparation method | |
RU2423111C2 (en) | EXTRACTS OF PLANT Chenopodium ambrosioides L, APPLIED IN CHINESE MEDICINE, COMPOSITIONS, INCLUDING SAID EXTRACTS, METHOD OF THEIR OBTAINING AND APPLICATION | |
CN1242810C (en) | Drug composition, its preparation method and use | |
CN1919270A (en) | Composition, exract, and pharmaceutical use thereof | |
CN1795914A (en) | Composition for treating throat oral disease, preparation and preparing method | |
CN1895458A (en) | Compound Chinese-medicinal extract for treating gynaopathy and its preparation | |
CN1274339C (en) | Anqi preparation | |
CN118976015A (en) | Rhein and rhein composition and application thereof | |
CN118477138A (en) | Preparation method and application of betel nut extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term |
Granted publication date: 20060816 |
|
CX01 | Expiry of patent term |